Response Scientific, Inc.™ (RSI) is a Life Sciences Biotechnology Corporation.

RSI’s mission is to improve people’s lives through innovative research leading to revolutionary new healthcare treatments.

RSI is focused on the field of Insulin Resistance and is advancing a prescription medication candidate code-named INS2. In early stage human testing INS2 has demonstrated the ability to repair insulin receptor cells, thereby lowering the amount of insulin required by people with both Type 1 and Type 2 Diabetes. INS2 may also be of benefit to sufferers of PCOS (polycystic ovarian syndrome), as well as Alzheimer’s, both of which are influenced by insulin resistance.

The initial target for INS2 is Diabetes, which effects the largest patient population. In the USA alone, data from the American Diabetes Association (ADA) indicates that 17.9 million people have been diagnosed with Diabetes. In the last 10 years newly diagnosed cases have accelerated to 1.6 million patients each year. A condition known as Pre-Diabetes is estimated to affect as many as 57 million additional people. INS2 could delay and/or prevent these patients from advancing to full-blown Diabetes.

Worldwide sales of insulin have skyrocketed in the last five years. In 2005 sales were under $8Billion while current projections for the year 2010 exceed $16Billion.

Aside from the growth of Diabetes itself, the reason can be attributed to physicians becoming more aggressive in the treatment of the disease. In order to get Diabetes under control quickly, a growing percentage of specialists have begun to prescribe insulin as the first choice of treatment.